Expert recommendations for targeted therapies in advanced NSCLC
Pediatric News ,
Osimertinib is the optimal first-line treatment for stage IV non–small cell lung cancer (NSCLC) with activating EGFR mutations…
Osimertinib is the optimal first-line treatment for stage IV non–small cell lung cancer (NSCLC) with activating EGFR mutations…
ASCO > Lung Cancer ASCO Expert Panel considers changes in evidence over last 3 years for updated guideline by Contributing…
Updated clinical guidance for advanced non-small cell lung cancer (NSCLC) provided additional support for first-line treatment…
Advertisement Paul J. Hesketh, MD AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and…